---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218282"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-05-12T12:48:29+00:00"
generated_at: "2026-05-12T12:52:04.815567+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics enters $30M at-the-market equity offering with Leerink Partners

## Summary
- Sales Agreement with Leerink Partners allows up to $30M gross proceeds from common stock sales on Nasdaq.
- Leerink receives 3.0% commission on gross proceeds; Company may sell at its discretion.
- Offering under existing shelf registration; no minimum obligation to sell.

## SEC filing metadata
- accession: 0001193125-26-218282
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-05-12T12:48:29+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526218282/0001193125-26-218282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526218282/d938051d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218282
- JSON: https://secwatch.observer/filing/0001193125-26-218282.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218282.txt

## Key facts
- Material Agreements
  Coya Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $30,000,000 (effective 2026-05-12).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Leerink Partners LLC
  - Value: up to $30,000,000
  - Effective: 2026-05-12
  source text: On May 12, 2026, Coya Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (“Leerink Partners”), pursuant to which the Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $30,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312526218282/0001193125-26-218282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.